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Ethylmalonic encephalopathy (EE) is a devastating infantile metabolic disorder affecting the brain, gastrointestinal
tract, and peripheral vessels. High levels of ethylmalonic acid are detected in the body fluids, and cytochrome c
oxidase activity is decreased in skeletal muscle. By use of a combination of homozygosity mapping, integration of
physical and functional genomic data sets, and mutational screening, we identified GenBank D83198 as the gene
responsible for EE. We also demonstrated that the D83198 protein product is targeted to mitochondria and
internalized into the matrix after energy-dependent cleavage of a short leader peptide. The gene had previously
been known as “HSCO” (for hepatoma subtracted clone one). However, given its role in EE, the name of the gene
has been changed to “ETHE1.” The severe consequences of its malfunctioning indicate an important role of the
ETHE1 gene product in mitochondrial homeostasis and energy metabolism.
Introduction
Ethylmalonic encephalopathy (EE [MIM 602473]) is an
autosomal recessive disorder that was originally re-
ported in Italian families (Burlina et al. 1991). Most of
the patients with EE described thereafter have been, with
a few exceptions (Yoon et al. 2001), of Mediterranean
(Burlina et al. 1991, 1994; Garavaglia et al. 1994;
Garcia-Silva et al. 1997; Grosso et al. 2002) or Arabic
(Ozand et al. 1994) descent. EE is characterized by
neurodevelopmental delay and regression, prominent
pyramidal and extrapyramidal signs, recurrent pete-
chiae, orthostatic acrocyanosis (fig. 1a), and chronic di-
arrhea, leading to death in the first decade of life. Sym-
metrical necrotic lesions in the deep gray matter
structures are the main neuropathological features of the
disease (fig. 1b). These lesions may be related to the
toxicity of metabolites that accumulate, or they may be
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secondary to the vascular changes commonly observed
in this disorder. EE is characterized by an unusual com-
bination of biochemical findings, which include persis-
tent lactic acidemia, elevated concentrations of C4 and
C5 plasma acylcarnitine species, markedly elevated uri-
nary excretion of ethylmalonic acid (EMA), and elevated
C4–6 acylglycines, notably isobutyrylglycine and 2-
methylbutyrylglycine. The specific activity of cyto-
chrome c oxidase is reduced in skeletal muscle (fig. 1c)
but not in fibroblasts. EMA can be derived from either
the carboxylation of butyryl-CoA, as a consequence of
disorders of the b-oxidation of short-chain fatty acids,
or from 2-ethylmalonic-semialdehyde, the final product
of the R-pathway catabolism of isoleucine (Mamer et
al. 1976; Nowaczyk et al. 1998). The differential di-
agnosis of persistent EMA aciduria is short-chain acyl-
CoA dehydrogenase deficiency, including the common
variants (Corydon et al. 2001), glutaric acidemia type
2 (sometimes described as ethylmalonic adipic aciduria)
(Mantagos et al. 1979), Jamaican vomiting sickness (Ta-
naka et al. 1976), and EE. However, none of the other
conditions has been associated with the peculiar clinical
features of EE, and extensive studies have consistently
failed to document a primary defect, in spite of a unique
clinical and biochemical phenotype. To achieve this goal,
we have successfully adopted a strategy based on pri-
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Figure 1 Clinical and biochemical features of EE. a, Skin areas with petechiae are indicated by arrows. The boxed pictures show
acrocyanosis of hands and feet. b, On T2–fluid-attenuated-inversion-recovery (FLAIR) MRI images of a transverse section of the brain, sym-
metrical, patchy, high-intensity signals are present in the head of nucleus caudatus and in the putamen (arrows). c, Histochemical reaction to
cytochrome c oxidase (COX) in skeletal muscle. The muscle of a patient with EE (top) shows a profound and diffuse reduction in COX
reactivity, compared with an age-matched control biopsy (bottom). d, Gas-chromatographic profile of urinary organic acids in EE. The abnormal
peak of EMA is indicated in red.
mary linkage analysis, followed by mutation analysis of
functionally selected candidate genes.
Methods
Patients and DNA Samples
We obtained informed consent from the parents of all
probands and siblings, as approved by the institutional
review board of the National Neurological Institute
“Carlo Besta,” before collecting blood or performing
skin biopsies. Several of our probands and families were
reported in previous publications describing EE. All pa-
tients had clinical and biochemical features typical of the
disease. Most of them were deceased before this study
began. Besides DNA samples, fibroblast or lymphoblas-
toid cell lines were established from some patients, but
no other tissues are currently available for further bio-
chemical or morphological investigation.
Linkage Analysis
The genomewide search was performed using the ABI
PRISM Linkage Mapping Set, version 2.5, on an ABI
PRISM 3100 DNA sequencer, and results were processed
by GENESCAN software. Alleles were assigned using
the GENOTYPER software. Statistical analysis was per-
formed assuming complete penetrance of a recessive dis-
ease. Pairwise linkage analysis and multipoint analysis
were performed using the LINKAGE computer package
and Simwalk2, respectively.
Bioinformatics
Integrative Genomics Analysis.—The integrative gen-
omics strategy (Mootha et al. 2003) is based on com-
parison between the RNA expression profiles of human
genes, the products of which are likely to be associated
with the mitochondrion, and the RNA expression pro-
files of the gene set contained in the relevant genomic
region—in our case, the 19q13 EE locus. The algorithm
reported by Mootha et al. was used to determine the
“neighborhood index” for each gene of the locus. The
index is a function of the number of mitochondrially
related genes found in a series of genes that share an
expression profile identical or very similar to that of the
proband gene. Identification of the probe set for each of
our candidate genes was obtained from the Affymetrix
expression profile database specific to the HG-U95A ar-
ray. The neighborhood index score for each probe set
was retrieved from the tables reported by Mootha et al.,
on an increasingly wider series of genes—namely, 100,
250, and 500.
Antibodies
A polyclonal antibody (anti-ETHE1C17) against an oli-
gopeptide encompassing amino acids 190 to 206 in the
C-terminus of the ETHE1 protein was raised in rabbits
by Neosystem, according to standard procedures. The
following mouse monoclonal antibodies were used in
the work: antihemoagglutinin (anti-HA) epitope of the
influenza virus (Roche) and anti–succinate-dehydroge-
nase (anti-SDH) (30-kDa subunit) (Molecular Probes).
In all experiments, the anti-ETHE1C17 antiserum was
used at a 1:2,000 dilution, the anti-HA antibody at a
final concentration of 2 mg/ml, and the anti–SDH anti-
body at a final concentration of 5 mg/ml.
Cell Cultures and Immunofluorescence Studies
All cell cultures were carried out in Dulbecco’s mod-
ified Eagle medium, supplemented with 10% fetal calf
serum at 37C in a 5% CO2 atmosphere. Immunoflu-
orescence (IF) was carried out on coverslip-plated cells.
In some experiments, cells were preincubated with 100
nM of MitoTracker Red dye (Molecular Probes) for 45
min at 37C, followed by fixation and incubation with
primary- and fluorescent-dye–conjugated secondary an-
tibodies, as described elsewhere (Tiranti et al. 1997). IF
was visualized by a confocal microscope (Biorad).
Western Blot Analysis
Approximately 2 # 106 cells were trypsinized, pel-
leted, sonicated, and solubilized, as described elsewhere
(Tiranti et al. 1999). SDS-polyacrylamide gel of 100–
200 mg protein/lane and western blot analysis were per-
formed by use of the ECL chemiluminescence kit (Amer-
sham), as described by Tiranti et al. (1999).
Cell Fractionation and Biochemical Assays
Standard methods were used for the preparation of
cell lysates, as well as digitonin-treated fibroblasts (Tir-
anti et al. 1999) and mitochondrial/postmitochondrial
fractions in cultured cells (Fernandez-Silva et al. 1997).
The specific activities of citrate synthase (Srere 1969)
and lactic dehydrogenase (Cornberg 1955) were mea-
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Table 1
Oligonucleotides for PCR Amplification of ETHE1 Exons
Exon Forward Primer Reverse Primer
1 5′-TCCGTGGCCCCTTTAAGGCGT-3′ 5′-CCCGGAGTTCCGTCCTTGCT-3′
2 5′-AGCAAGGACGGAACTCCGGG-3′ 5′-TCCCATTCCACTGACGCTGCA-3′
3 5′-TGCAGCGTCAGTGGAATGGGA-3′ 5′-AAGAAGTCCAGGCCACCACC-3′
4 5′-GGGCCAGTTTCATCTAGAAGGC-3′ 5′-GCCCCCTAAAAGTCTAATGTCC-3′
5 5′-GGAAGGGGTTAGAGTCTTCTGT-3′ 5′-GAGACTGGTCGTCTTCATGCC-3′
6 5′-AGTTCTGAGAGGCCTGAGGCA-3′ 5′-ACCCAGGAGTCCAAGACCCCA-3′
7 5′-AGTGGGGCCTGGAACTCTAC-3′ 5′-CGGCCCAGAAACCCAATTGG-3′
sured as enzymatic markers for mitochondrial and cy-
tosolic fractions, respectively. Glyoxalase II (Glyo-II)–
specific activity was measured spectrophotometrically,
after the glutathione-dependent reduction of DTNB
(5,5′-di-thio-bis-(2)-nitrobenzoate) to TNB (thio-nitro-
benzoate) at 412 nm, by use of S-lactoyl-glutathione
(Sigma) as a substrate (Ridderstro¨m et al. 1996). The
reaction was carried out at 37C in 100 mM MOPS (3-
[N-morpholino]propanesulphonic acid), pH 7.5, 200
mM DTNB, 0.1% Triton X-100, and 900 mM S-lactoyl-
glutathione, with a molar extinction coefficient () of
13.6 mM1.
Mitochondrial Targeting
For mitochondrial targeting (Tiranti et al. 1997), cel-
lular proteins were radiolabeled with 35S-methionine for
2 hr in the presence or absence of 20 mM valinomycin.
The specific translation products were immunoprecipi-
tated using the anti-HA–specific monoclonal antibody in
the presence of the protein A-agarose (Roche) and elec-
trophoresed through a 15% SDS-polyacrylamide gel. Af-
ter fixation in 10% acetic acid and 25% isopropanol, the
gel was washed for 20 min in Amplify reagent (Amer-
sham) and layered onto a phosphorimaging screen
(Biorad). After overnight exposure, autoradiography was
carried out in a Molecular Imager apparatus (Biorad).
For proteinase K protection, mitochondria from hu-
man fibroblasts, freshly isolated as described elsewhere
(Fernandez-Silva et al. 1997), were incubated for 20 min
at 37C with 0, 100, and 250 mg/ml proteinase K and
with 0.5% Triton X-100, supplemented with 250 mg/ml
proteinase K. For suborganellar localization, human fi-
broblast mitochondria were treated with three cycles of
freezing and thawing and six sonication strokes on ice-
cold water, and the membrane and soluble fractionswere
separated by ultracentrifugation at 100,000 # g for 1
hr at 4C. After SDS-PAGE through a 15% polyacryl-
amide gel, the ETHE1 protein was visualized by western
blotting by use of anti-ETHE1C17.
Miscellaneous RNA and DNA Manipulations
ETHE1 Cloning.—A full-length human ETHE1 cDNA
was retrotranscribed and PCR-amplified from total
RNA extracted from human fibroblasts, by use of stan-
dard procedures (Tiranti et al. 1997). The following ol-
igonucleotides were used for RT-PCR: 5′-GCTCGGCC-
TCCGCTCATTCCTGAC-3′ (forward primer) and
5′-GGCAGTGGGTGTCTGCACCCCACA-3′ (reverse
primer). Each of the 30 PCR amplification cycles was
70C for 2 min and 95C for 1 min. The cDNA was
cloned into the plasmid vector of the TOPO-TA cloning
kit (Invitrogen), according to the instruction manual of
the kit.
Generation and Cloning of ETHE1HA Recombinant Pro-
teins.—The human ETHE1 cDNA was tagged on the 3′
end with the sequence encoding an epitope of the influ-
enza virus HA, essentially as described elsewhere (Tiranti
et al. 1997). A second ETHE1 cDNA encoding a shorter
HA-tagged variant protein starting at P21 amino acid
residue (ETHE121) was PCR-amplified from the HA-
tagged ETHE1-encoding construct, by use of suitable
oligonucleotides as primers. Both constructs were in-
serted into the eukaryotic-expression plasmid vector
pcDNA3.1 (Invitrogen) by use of suitable restriction
sites. The recombinant plasmids were transfected by
electroporation in Cos-7 (for transient expression) or
HeLa (for stable expression) cells, as described elsewhere
(Tiranti et al. 1997).
Northern Blot.—A premade multiple-tissue northern
blot (MTN), containing 1 mg/lane of purified polyA
RNA (Clontech), was preincubated in ExpressHyb hy-
bridization solution (Clontech) for 30 min at 65C and
then was hybridized for 2 hr at 65C with a human
ETHE1 cDNA probe (32P), which was radiolabeled us-
ing the Ready-To-Go DNA Labelling Beads kit (Amer-
sham). The MTN filter was exposed overnight and vi-
sualized by a Molecular Imager apparatus (Biorad).
Genotyping
Nucleotide sequence analysis was carried out on a
3100 ABI Automated Sequencer on samples prepared
using the BigDye Termination kit (Applied Biosystems).
Data were elaborated using the Secscape software (Ap-
plied Biosystems). Oligonucleotides for the PCR ampli-
fication of the seven exons of the human ETHE1 gene
are listed in table 1.
Tiranti et al.: ETHE1 Mutations in Ethylmalonic Encephalopathy 243
Figure 2 Pedigrees. The blackened symbols indicate the subjects with EE, and the unblackened symbols indicate the clinically healthy
individuals. Beside each symbol are shown the individual haplotypes, covering a 3-cM region on chromosome 19q13. The markers from which
the haplotypes were constructed and their genetic distances are shown in the boxed area against a chromosome-19 idiotype. The ETHE1 gene
is flanked by markers D19S420 and D19S408.
PCR amplification conditions were 94C for 1 min,
59C for 30 s, 72C for 1 min, for 32 cycles, plus an
initial denaturation step at 94C for 3 min and a final
extension at 72C for 2 min. Exons 2 and 7 were am-
plified in a buffer containing 3.1 mM MgCl2, 35%
deionized formamide, and 10% glycerol (final concen-
trations). PCR amplification cycles were as above, except
that the annealing temperature was 57C.
Results
Identification of the EE Locus on Chromosome 19q13
A full genomewide scan of four consanguineous
and two nonconsanguineous families (fig. 2) showed a
maximum pairwise LOD score of 4.35 at a recombi-
nation frequency (v) of 0 with marker D19S420 on
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Figure 3 Genetic findings. a,Multipoint analysis of the EE locus
for the families shown in figure 2. b, Integrative genomics strategy
based on calculation of the mitochondrial neighborhood index. On
the X-axis is shown the number of genes with expression profiles that
were considered for the calculation of the index. The graph reports
the values obtained for genes (UCSC annotation) from the 19q13 EE
locus for which scores were equal to or higher than a threshold (gray
area) corresponding to the score reported by Mootha et al. for the
LRPPRC gene. YF13H12 (underlined) corresponds to a partial-length
ETHE1 cDNA.
chromosome 19q13. The critical interval was defined
within a region of ∼3 cM, between markers D19S223
and D19S559. Multipoint analysis (Lathrop et al. 1984)
detected a maximum location score of 7.21 (fig. 3a).
Haplotype reconstruction (Sobel and Lange 1996) re-
vealed a homozygous condition caused by identity-by-
descent alleles in all affected individuals of the four con-
sanguineous families. The two nonconsanguineous
families contributed no further narrowing of the critical
region. One of these families, family E, showed an ex-
tended homozygous region in the proband, suggesting
unrecognized parental consanguinity.
Search for Candidate Genes
The genomic sequence betweenmarkers D19S223 and
D19S559 contains ∼130 known or predicted genes,
based on concordant data obtained from the NCBI,
CELERA, and UCSC genome browser databases. Be-
cause of the clinical and biochemical features of EE, we
assumed that the responsible protein is likely to be in-
volved in mitochondrial metabolism. We first excluded
mutations in BCKDHA, which encodes the a polypep-
tide of branched-chain ketoacid dehydrogenase E1, as
well as mutations in TOM40, which encodes the 40-
kDa subunit of the outer mitochondrial membrane
transport machinery. We then selected candidate genes
that predict proteins of unknown function, which may
potentially be related to mitochondria. We followed an
integrative genomics approach that was originally de-
veloped to identify LRPPRC, the gene responsible for
cytochrome c oxidase deficiency, Saguenay–Lac-Saint-
Jean type (MIM 220111) (Mootha et al. 2003). Ac-
cording to this strategy, a “neighborhood index” was
given to all genes of the critical region; this index reflects
the similarity of their RNA-expression profiles to those
of known mitochondrial genes.
ETHE1 Is the Gene Responsible for EE
Among the seven genes (including BCKDHA) that
were given the highest scores (fig. 3b), a likely candidate
was a gene annotated as UCSC entry YF13H12, gener-
ically associated with a protein “present in thyroid.” A
BLAST search against human ESTs showed that
YF13H12 corresponded to a partial-length cDNA of
GenBank D83198. This gene was previously known as
“HSCO” (hepatoma subtracted cDNA library clone
one), a gene overexpressed in human hepatoma cell cul-
tures (Higashitsuji et al. 2002). However, in light of its
role as the gene responsible for ethylmalonic encepha-
lopathy, the name of the gene has been changed to
“ETHE1.” We showed that human ETHE1 is ubiqui-
tously expressed as a single, ∼1,000-nucleotide (nt)–long
transcript (fig. 4a). The ETHE1 gene encodes a protein
that shares similarities with human Glyo-II (fig. 4b). We
observed that this protein contains an amino (N)-ter-
minal sequence of 24 amino acids, which was missing
in the polypeptide predicted by YF13H12. This N-ter-
minal region is rich in apolar and basic (mostly R) res-
idues, similar to mitochondrial leader peptides (Attardi
and Schatz 1988). When analyzed by dedicated software
packages available online (Mitoprot-2, PSORT-II, Pre-
dotar, and TargetP), the predicted ETHE1 protein se-
quence showed a very high likelihood of being targeted
to mitochondria (not shown). This analysis also sug-
gested two potential cleavage sites for the mitochondrial
processing peptidase (MPP), between either A20 and P21
or R11 and Q12.
Mutation Analysis.—In light of these observations, we
sequenced the seven exons (fig. 5a) of the ETHE1 gene
from patients with EE (table 2). Homozygous mutations
were found in all probands from the four consanguin-
eous families (A–D) originally used for gene mapping.
The proband from family E carried a homozygous mu-
tation, whereas the proband from family F was a com-
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Figure 4 ETHE1 transcript and protein. a, Northern blot analysis of ETHE1 transcript on polyA mRNA extracted from different
human tissues. B, brain; H, heart; M, skeletal muscle; C, colon; T, thymus; S, spleen; K, kidney; L, liver; I, small intestine; P, placenta; Lu, lung;
Bl, blood. The 1,000-nt ETHE1 transcript is indicated by an arrow. b, Multiple alignments of the ETHE1 protein sequences in different species.
Protein sequences were aligned using CLUSTALW. Amino acid substitutions are shown below the alignment, except for the I replacing the first
M. A thick bar indicates the b-lactamase signature.
pound heterozygote. Mutations were also found in eight
additional probands belonging to four consanguineous
(G–J) and two nonconsanguineous (K, L) families, as
well as in four unrelated singleton patients (M–Q). Co-
segregation of the mutations with the disease was dem-
onstrated in all families (not shown).
Most of the 16 different mutations found in our co-
hort (table 2 and fig. 5a) were loss-of-functionmutations
producing a stop, a frameshift, or aberrant splicing. In
one consanguineous family, the entire gene was missing,
and, in two others, exon 4 of the gene was missing in
both alleles. Six missense mutations were detected, all
predicting amino acid changes in highly conserved po-
sitions (fig. 4b).
Haplotype reconstruction in the two families lacking
exon 4 showed an identical set of microsatellite poly-
morphisms, indicating that these families are related.
This result is concordant with a common geographic
origin of the families. An identical missense point mu-
tation, 487CrT, predicting an R163W amino acid
change, was found in three unrelated probands, but in
this case the haplotypes differed from each other, sug-
gesting that the mutational event had occurred either
independently or in a very ancient common progenitor.
None of the missense mutations was detected in 200
DNA samples from unrelated control individuals from
Italy.
Western Blot Analysis.—A polyclonal antibody was
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Figure 5 Characterization of ETHE1 gene and protein (ETHE1) in patients with EE. a, ETHE1 mutations identified in our patients.
Mutations are indicated along the schematic representation of the ETHE1 cDNA. Exons are numbered in the cDNA scheme. The dark grey
areas represent the 5′ and 3′ UTRs. The genomic organization of human ETHE1 is represented below the cDNA. b, Western blot analysis on
cell lysates and isolated mitochondria from HeLa- and HeLaETHE1-derivative cell lines, using the anti-ETHE1C17 and anti-HA antibodies. The
filter was treated with anti-ETHE1C17 and then stripped and rehybridized with the anti-HA antibody. The two antibodies show a virtually
identical pattern in the HeLaETHE1 cell line, whereas ETHE1 protein CRM is barely detected by anti-ETHE1C17 antibody in naive, untransfected
HeLa cells. c, Western blot analysis on fibroblast lysates was performed using anti-ETHE1C17; a monoclonal antibody specific for SDH-B, the
30-kDa subunit of succinate dehydrogenase, was used as a control. The same filter was first treated with anti-ETHE1C17 and then stripped and
rehybridized with the anti-SDH antibody. C1 and C2 denote control fibroblasts. The upper and lower arrows indicate the precursor and mature
ETHE1 polypeptides, respectively. Lanes A, B, E, I, J, K, and Q show fibroblasts from patients with EE. Each letter refers to the corresponding
proband (and mutations) listed in table 2.
raised in rabbit against a synthetic peptide correspond-
ing to the last 17 amino acids on the carboxy (C)-ter-
minal end of the human ETHE1 protein product (anti-
ETHE1C17). The specificity of the anti-ETHE1C17
antibody was tested by immunostaining HeLa cell lys-
ates that stably express a recombinant, influenza-virus-
HA–tagged ETHE1 (ETHEHA) protein product. The
western blot pattern obtained using the anti-ETHE1C17
antibody was virtually identical to that produced by an
anti-HA monoclonal antibody, indicating the specificity
of anti-ETHE1C17 for the ETHE1 protein (fig. 5b). The
anti-ETHE1C17 antibody was used to immunostain
ETHE1 protein–specific crossreacting material (CRM)
for western blot analysis on fibroblast cell lines from
patients with EE and controls (fig. 5c). A band corre-
sponding to the mature ETHE1 polypeptide was clearly
detected in fibroblast lysates from two control individ-
uals. A much fainter band of slightly slower mobility
was also detected in the same samples andwas attributed
to the precursor ETHE1 protein species retaining the
mitochondrial N-terminal leader peptide (see below).No
ETHE1 protein CRM was detected in any EE fibroblast
cell line, including missense, splicing, and deletion
mutations.
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Table 2
Mutation Screening
Familiesa
No. of
Patients Mutation Localization
Predicted Transcript
or Protein Abnormality
A 1 604_605insG EX6 V202fsX220
B 1 3GrT EX1 M1I
C 3 del exon 4 EX4 Not translated
D 1 487CrT EX4 R163W
E 1 406ArG EX4 T136A
F 1 221_222insA/440_450del11 EX2/4 Y74X/H147fsX176
G 1 221_222insA EX2 Y74X
H 2 del exons 1–7 EX1–7 Not translated
I 1 del exon 4 EX4 Not translated
J 1 5051GrT EX4/IN4 Splicing error
K 1 3755GrA EX3/IN3 Splicing error
L 2 131_132delAG/488GrA EX2/4 E44fsX105/R163Q
M 1 592_593insC EX5 H198fsX220
N 1 487CrT EX4 R163W
O 1 5051grA EX4/IN4 Splicing error
P 1 487CrT EX4 R163W
Q 1 113arG/554TrG EX2/5 Y38C/L185R
NOTE.—Nucleotides are numbered considering the A of the first ATG codon as1. Amino acids
are numbered considering the initiation M as 1.
a A–D, families shown in figure 3; E–L, additional families in which segregation analysis could
be performed; M–Q, families composed of singleton patients (no other family member available
for analysis).
The ETHE1 Gene Product Is a Mitochondrial Matrix
Protein
Import of the ETHE1HA Protein In Vivo.—Using an anti-
HA–specific monoclonal antibody, two 35S-radiolabeled
protein species, of ∼30 kDa and ∼29 kDa, were im-
munoprecipitated from COS-7ETHE1 and HeLaETHE1 cells.
The 30-kDa polypeptide is the radiolabeled ETHE1HA
protein. The second, slightly shorter product is the ma-
ture form of the ETHE1HA protein, resulting from the
intramitochondrial cleavage of a leader peptide (Attardi
and Schatz 1988). This is cleaved from the N-terminal
end of the polypeptide, since the mature protein still
contains the HA epitope, which is fused with the protein
C-terminus. The import process is energy dependent (At-
tardi and Schatz 1988), since it was inhibited by treat-
ment with valinomycin, a mitochondrion-specific ion-
ophore that abolishes the mitochondrial proton-motive
force (DW).
We estimated that the leader peptide must be !20
amino acid residues, because the size of the mature
ETHE1HA protein is bigger than that of ETHE121
HA, a
recombinant ETHE1HA protein variant missing the first
20 amino acids on the N-terminus.
Immunofluorescence Studies.—In COS-7 cells tran-
siently expressing the ETHE1HA protein (COS-7ETHE1),
as well as in stably expressing HeLa cells (HeLaETHE1)
(fig. 6b), the immunofluorescence pattern specific to the
ETHE1HA protein was virtually identical to that obtained
by using MitoTracker, a mitochondrion-specific immu-
nofluorescent dye.
Protease-Protection Test.—To determine which mito-
chondrial compartment contains the mature ETHE1
protein product, a protease-protection test (McQuibban
et al. 2003) was performed on mitochondria isolated
from human fibroblasts. As shown in figure 6c, the
ETHE1 protein–specific CRM was protected from pro-
teolytic digestion with increasing concentrations of pro-
teinase K in intact mitochondria, whereas it was com-
pletely digested by proteinase K in detergent-treated
mitochondria. These results indicate that the mature
ETHE1 protein product is located in the inner com-
partment of mitochondria.
Suborganellar Localization.—To establish whether the
mature ETHE1 polypeptide is a matrix- or a membrane-
bound protein, western blot analysis was carried out
using anti-ETHE1C17 against different suborganellar
fractions of human mitochondria. As shown in figure
6d, marked enrichment of ETHE1 protein CRM was
obtained in the total mitochondrial fraction compared
with the cell lysate, whereas no CRM was observed in
the supernatant obtained after isolation of mitochon-
dria. When the suborganellar fractions were analyzed,
virtually all the ETHE1 protein–specific CRMwas found
in the soluble fraction, which largely corresponds to the
mitochondrial matrix, whereas no ETHE1 protein–spe-
cific CRM was observed in the lane corresponding to
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Table 3
Glyo-II–Specific Activities
MEAN  SD GLYO-II ACTIVITY
(nM/min/mg protein)
CELL TYPE (NO. OF SAMPLES) Cytosol Mitochondria
HeLa ( )np 4 77.2  13.4 5.2  2.5a
HeLaETHE1( )np 4 69.5  6.3 7.2  2.3a
Control fibroblasts ( )np 5 45.4  9.1 3.0  0.96b
EE fibroblasts ( )np 4 54.3  9.4 3.2  1.25b
a Isolated mitochondria.
b Mitochondrion-enriched fraction from digitonin-treated cells.
Figure 6 Mitochondrial localization of the ETHE1 protein. a, Mitochondrial import in vivo. Autoradiographs of 35S-radiolabeled HA-
tagged ETHE1 protein, immunoprecipitated from HeLaETHE1 and Cos-7ETHE1 cell lysates. Arrows indicate the HA-tagged ETHE1 precursor
protein, mature ETHE1 protein, and ETHE121, a shortened HA-tagged ETHE1 protein species lacking the first 20 amino acid residues on the
N-terminus. Experiments were carried out in the presence () or absence () of valinomycin. b, Confocal immunofluorescence on Cos-7ETHE1
(panels 1–3 depict transient transfection) and HeLaETHE1 (panels 4–6 depict stable transfection). The green fluorescence in panels 1 and 4
corresponds to ETHE1HA protein–specific immunoreactivity. The red fluorescence in panels 3 and 6 corresponds to mitochondrial staining by
MitoTracker, a mitochondrion-specific dye. The two immunofluorescence patterns largely overlapped, as shown by confocal merge images in
panels 2 and 5. Magnification 40#. c, Proteinase K (PK)-protection assay by western blot analysis on freshly isolated mitochondria from human
fibroblasts. Lanes 1–3 show intact isolated mitochondria treated with 0, 100, 250 mg/ml PK; lane 4 shows mitochondria treated with 0.5%
Triton X-100 before digestion with 250 mg/ml PK. Anti-ETHE1C17 was used as the primary antibody. d, Suborganellar localization of the ETHE1
protein by western blot analysis on mitochondria isolated from human fibroblasts. Lane 1, cell lysate; lane 2, postmitochondrial supernatant
(10,000 # g); lane 3, intact mitochondria; lane 4, mitochondrial membrane fraction; lane 5, mitochondrial soluble fraction. Anti-ETHE1C17
was used as the primary antibody.
the membrane fraction. Identical results were consis-
tently obtained on mitochondria isolated from rat and
mouse liver (not shown).
Glyo-II Activity Assay
To test whether the mature ETHE1 protein is a mi-
tochondrial Glyo-II, we measured the Glyo-II–specific
activity in isolated mitochondria from naive HeLa and
HeLaETHE1 cells. As shown in figure 2d, the ETHE1 pro-
tein CRM is virtually absent in naı¨ve HeLa cells, whereas
it is robustly expressed in HeLaETHE1 cells. Nevertheless,
very low, comparable Glyo-II activities were measured
in isolated mitochondria from both cell lines, whereas
abundant activities were detected in the postmitochon-
drial supernatants, due to the presence of cytosolic Glyo-
II (table 3). Likewise, Glyo-II activity was present in the
cytosolic fraction of both control and EE fibroblasts,
whereas it was almost undetectable after the elimination
of the cytosolic fraction from the same cells by treatment
with digitonin (table 3). In any case, no difference was
measured between control and EE cells in the mito-
chondrial-enriched fraction.
Discussion
Using a combination of homozygosity mapping, inte-
gration of physical and functional genomic data sets,
and mutational screening, we identified ETHE1 as the
gene responsible for EE. An integrative genomic ap-
proach was adopted to select a list of a few candidate-
for-function genes out of 1130 sequences present in the
critical interval defined by linkage analysis. The success
of this strategy in our project, as well as in the original
work on the identification of the gene responsible for
Leigh syndrome, French-Canadian type, confirms it as
a powerful method for the discovery of genes responsible
for mitochondrial, and possibly nonmitochondrial, in-
herited disorders.
Localization of ETHE1 Mature Protein in the
Mitochondrial Matrix
We identified ETHE1 as a candidate gene on the basis
of the observation that its expression is concordant with
that of human genes known to encode proteins targeted
to and/or functionally associated with mitochondria.
Previous observations by Higashitsuji et al. (2002) sug-
gested that ETHE1 (formerly HSCO) is diffusely present
in the cytoplasm of cultured cells and is occasionally
found in the nucleus, possibly acting as a shuttle protein
controlling the nucleus-cytoplasm trafficking of the tran-
scription factor NF-kB. In immunofluorescence experi-
ments, we consistently failed to observe a nuclear lo-
calization of the ETHE1 protein in human cell cultures,
in both native conditions and after treatment with lep-
tomycin B, an inhibitor of nuclear export (not shown).
By contrast, we have clearly demonstrated that themain,
if not exclusive, localization of this protein is confined
to the mitochondrial matrix. In particular, we showed
that, for most proteins targeted to mitochondria, a ca-
nonical mitochondrial leader peptide, which is present
at the N-terminus of the full-length ETHE1 protein, ad-
dresses the protein to the organelle and is cleaved off
after internalization in the inner mitochondrial com-
partment through an energy-dependent process, presum-
ably carried out by MPP. This conclusion is the result
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of several experimental approaches: in vivo mitochon-
drial import assays; immunofluorescence-based colocal-
ization of the ETHE1 protein–specific CRM with mi-
tochondrion-specific dyes; protease-based protection
assays on intact and disrupted organelles; and ETHE1
protein immunotitration on human cell fractions, iso-
lated mitochondria, and mitochondrial subfractions.
Structure and Function of the ETHE1 Protein
The function of the ETHE1mature protein is presently
unknown. The ETHE1 protein is a phylogenetically con-
served protein, sharing high homology with Glyo-II. Be-
sides Glyo-II, a BLAST-P search, with the human ETHE1
predicted protein sequence as a probe, resulted in the
identification of highly similar proteins in all metazoan
species, in plants, such as Arabidopsis thaliana, and in
fungi, such as Saccharomyces cerevisiae (fig. 3b). In con-
trast with the remaining portion of these protein se-
quences, the first 20–30 amino acid residues on the N-
terminus appear to be poorly conserved. However, when
the sequences shown in figure 4b were analyzed by or-
ganellar target–prediction softwares, a high score for
mitochondrial targeting was obtained for all of them,
with the exception of Glyo-II, which is known to be a
cytosolic enzyme. These results suggest the existence of
a distinct family of mitochondrial proteins that is present
in all eukaryotes and is structurally—and possibly func-
tionally—similar to the human ETHE1 protein.
The glyoxalase system catalyzes the conversion of
toxic 2-oxoaldehydes into the corresponding 2-hydroxy
acids (Thornalley 1990). The main substrate seems to
be methylglyoxal, which is formed as a by-product of
glycolysis from triose phosphates through the action of
triose-phosphate isomerase but also via other metabolic
routes. As the first step of the glyoxalase system, methyl-
glyoxal reacts spontaneously with reduced glutathione
to form a hemithioacetal. Glyoxalase I converts hemi-
thioacetal into S-D-lactoylglutathione, which is further
metabolized to D-lactate and glutathione by Glyo-II.
Both glyoxalase I and II are cytosolic enzymes. However,
in the yeast S. cerevisiae, in addition to the cytosolic
Glyo-II, encoded by the gene GLO2, a second Glyo-II,
encoded by the GLO4 gene, is targeted to mitochondria
(Bito et al. 1997). The GLO4 protein contains an N-
terminal leader peptide with a Mitoprot-2–predicted
MPP cleavage site at 21, similar to the prediction for
the ETHE1 protein. However, the leader peptide of
GLO4 has been experimentally demonstrated to be
much shorter—only 10 amino acids, including the ini-
tiation M residue (Bito et al. 1997). These results are
similar to those obtained by us for the ETHE1 precursor
protein, which also appears to have a very short leader
peptide, possibly between R11 and Q12, as predicted by
the TargetP program. It is interesting that only the ma-
ture form of GLO4, lacking the 10-amino-acid–long
mitochondrial leader peptide, shows Glyo-II activity,
whereas the uncleaved precursor form is completely in-
active (Bito et al. 1999). Glyo-II, GLO4, and the ETHE1
protein all contain a metallo-b-lactamase region that, in
the ETHE1 protein sequence, encompasses amino acid
residues 35–196. A consensus signature sequence,
HXHXD(X)H, is conserved throughout the b-lactamase
protein family and is believed to be the Zn(II) ligand
(Aravind 1999). In addition, the ETHE1 protein se-
quences in humans, mice, and other organisms contain
the Y residue, which is present in human Glyo-II (at
position 175) and in GLO4 (at position 200) and is
believed to be part of the binding site for glutathione
(Ridderstro¨m et al. 2000). The similarities of the ETHE1
protein with both Glyo-II and GLO4, the conservation
of the b-lactamase signature and the glutathione binding
site, as well as the abnormalities in mitochondrial met-
abolic pathways associated with EE, all suggest that the
main role of the mature ETHE1 protein is that of an
enzyme, possibly a metallo-b-lactamase. Nevertheless,
our experiments, performed onmammalian cell cultures,
failed to demonstrate a significant Glyo-II activity in
isolated mitochondria, using D-lactoylglutathione as a
substrate. A likely possibility is that the ETHE1 protein
could still be a mitochondrial metallo-b-lactamase in-
volved in the metabolism of an unknown substrate. Al-
ternatively, its activity as a mitochondrial Glyo-II could
vary in different tissues and growth conditions; for in-
stance, robust Glyo-II activity has been reported in iso-
lated mitochondria from rat (Talesa et al. 1989) and
bovine liver (Talesa et al. 1990), and our preliminary
data (not shown) have confirmed these findings.
Pathogenic Mechanism of ETHE1 Mutations in EE
We have identified 16 different ETHE1 mutations in
several families or singleton patients with EE. The fol-
lowing evidence supports the idea that mutations are of
pathogenic significance in ETHE1, thus specifying
ETHE1 as the EE gene: (1) the absence of mutations in
ethnically matched controls; (2) the occurrence of mu-
tations that clearly predict a loss of function of the re-
sulting protein; (3) the occurrence of a few missense
mutations that all affect phylogenetically conserved
regions in eukaryotes, and, with the exception of the
T136A mutation, are largely nonconservative in nature;
(4) their strict cosegregation with disease in all families
analyzed; and (5) the absence of the mutant protein in
several fibroblast cell lines from patients with EE ex-
amined by western blot analysis. Taken together, the
above observations indicate that EE is a genetically ho-
mogeneous disorder caused by the loss of function of
mutant ETHE1. This conclusion is fully compatiblewith
the recessive behavior of the disease trait and is again
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suggestive of a defect in a still-unknown enzymatic ac-
tivity related to mitochondrial energy metabolism.
Clinical Implications
Even though EE has been described mainly in families
from the Mediterranean basin and the Arabian penin-
sula, we obtained no evidence of the existence of an
ancestral haplotype or a cluster of common mutations
in our cohort of patients with EE. The identification of
the gene responsible for EE offers a tool for early di-
agnosis and rational genetic counseling. Since the initial
report, no more than 30 cases of EE have been described
worldwide, leading to the assumption that EE is a very
rare autosomal recessive disorder. However, the actual
incidence of this condition could have been significantly
underestimated because the biochemical phenotype may
be incorrectly attributed to other metabolic disorders,
particularly defects of the mitochondrial electron-trans-
fer flavoprotein pathway. In the experience of the au-
thors, several cases of EMA aciduria are initially given
a biochemical diagnosis of glutaric acidemia type II, but
this diagnosis is not confirmed by in vitro enzyme assays
and/or molecular studies. We believe that some of these
cases could be EE.
Although the function of the ETHE1 protein remains
to be elucidated, the evidence that its loss causes EE
indicates that the activity of the protein is required for
maintaining important metabolic homeostasis in the mi-
tochondria and in the whole organism. This is also sup-
ported by the ubiquitous expression of the ETHE1 tran-
script in humans and by the diffusion of the ETHE1
protein family among eukaryotic species.
With appropriate model systems, in which we syste-
matically manipulate ETHE1 expression, it should be
possible to establish the role of this gene in mitochon-
drial homeostasis, leading to an understanding of EE
pathogenesis.
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